Bernstein’s Steven Winoker and team contend that Brexit is “bad for all our companies it is just a matter of degree.” They explain why Tyco International (TYC), Idex (IEX), Danaher (DHR),Honeywell International (HON) and Emerson Electric (EMR) could feel some degree of pain:
While the direct revenue exposure to the UK is relatively small across our coverage (aside fromTyco and Idex), the potential impact from Brexit is much more widespread across the continent and the world. The impact should be most negative for our companies with larger industrial exposure to Europe, just as we have begun to hear incrementally positive commentary regarding Europe.Idex andTyco have some of the highest direct exposures to UK and Europe but Tyco’s business should be relatively more stable and in any case theJohnson Controls (JCI) synergies loom large. Eaton (ETN) and Emerson Electric, though with slightly smaller exposure, are more involved with industrial spending.Danaher andHoneywell have high revenue exposure, but we believe that their more benign end market exposure should mitigate some of the negative consequences they face. We rate Allegion (ALLE), Danaher, Dover (DOV), Fortive (FTV), Honeywell, Ingersoll-Rand (IR), Pentair (PNR) andTy co Outperform; Emerson Electric, Eaton, General Electric (GE),Idex and 3M (MMM) Market-Perform; Rockwell Automation (ROK) Underperform.
5 Best Performing Stocks To Buy For 2016: Avanir Pharmaceuticals Inc(AVNR)
Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
- [By Paul Ausick]
Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analysts upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.
5 Best Performing Stocks To Buy For 2016: Merck & Company, Inc.(MRK)
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, c hickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- [By Ben Levisohn]
Merck (MRK) has dropped 2.8% to $49 after the pharmaceutical giant beat earnings forecasts but offered guidance that fell short of expectations.
- [By Ben Levisohn]
Late Tuesday, Gilead Sciences (GILD) won a court ruling in its battle with Merck (MRK) over the intellectual property rights behind its blockbuster hepatitis-C drugs Harvoni and Sovaldi. Gabelli’s Jing He stands by her contention that Gilead is “the most undervalued stock” in biotech:
Hot Oil Service Companies For 2016: Medidata Solutions, Inc.(MDSO)
Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. It offers Medidata Rave, a platform for capturing, managing, and reporting clinical data; Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, which enhances the efficiency of clinical trial start-up; Medidata Insights, a clinical business analytics platform; and Medidata Balance, a randomization and trial supply management solution. The company also provides Medidata Patient Cloud application for electronic patient-reported outcome; Medidata Grants Manager, which enables to develop and manage trial budgets; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and Medidata SQM, a set of c loud-based site quality management dashboards. In addition, it offers Medidata Coder that provides medical coding and synonym management solutions; Medidata Safety Gateway, which offers a solution for collecting and transmitting adverse events and related data from the EDC system; and Medidata Targeted SDV that provides auditable and scalable solutions, as well as offers hosting, support, and professional services. Medidata Solutions, Inc. markets and sells its cloud-based solutions through direct sales force, as well as through relationships with CROs and other strategic partners. The company serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and academic institutions, contract research organizations, and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.
- [By Lisa Levin]
On Wednesday, technology shares climbed by 0.94 percent. Top gainers in the sector included Marvell Technology Group Ltd. (NASDAQ: MRVL) and Medidata Solutions Inc (NASDAQ: MDSO).
5 Best Performing Stocks To Buy For 2016: Insys Therapeutics, Inc.(INSY)
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.
- [By Motif Investing]
Cannabis consulting business Medicine Man Technologies Inc (OTC: MDCL) is one such company that started trading over the counter earlier this year. Terra Tech Corp (OTC: TRTC), Insys Therapeutics Inc (NASDAQ: INSY) and GW Pharmaceuticals plc (NASDAQ: GWPH) are two other companies that investors can access.
5 Best Performing Stocks To Buy For 2016: Lands' End, Inc.(LE)
Lands’ End, Inc. (Lands’ End), incorporated on August 19, 1986, is a multi-channel retailer of casual clothing, accessories and footwear, as well as home products. The Company operates through two segments: Direct and Retail. The Company offers products through catalogs, online at www.landsend.com.
The Direct segment sells products through the Company’s e-commerce Websites, international Websites and direct mail catalogs. The Retail segment sells products and services through Lands’ End Shops at Sears across the United States, the Company’s standalone Lands’ End Inlet stores and international shop-in-shops. The Company’s retail properties consist of approximately 227 Lands’ End Shops at Sears, which averages approximately 7,700 square feet, 14 Lands’ End Inlet stores, which averages approximately 9,300 square feet, and over five shop-in-shops in the United Kingdom.
The Company’s product categories include Apparel and Non-apparel. The Non-apparel c ategory offers accessories, footwear and home goods. The Company provides embroidery, monogramming, gift wrapping, shipping and other services. It offers products for men, women and kids. It offers swimsuits, knit tops and tees, shirts and blouses, sweaters, pants, jeans, shorts, dresses, skirts, activewear, coats, sleepwear, shoes, accessories and bags for women. It offers dress shirts, casual shirts, polo shirts, knit tops and tees, shoes, bags, sweaters, swimwear and accessories for men. It offers swimsuits, tops, blazers and jackets, outerwear, and pants and leggings for kids. In addition, the Company offers sheets and pillowcases, duvet covers and comforters, blankets and throws, mattress pads, towels, rugs and mats, school uniforms and shower curtains.
- [By Monica Gerson]
Lands’ End, Inc. (NASDAQ: LE) is estimated to report its quarterly earnings at $0.02 per share on revenue of $293.24 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets